1. Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date

   • Qi Zhao

   Leading Article 08 January 2020 Pages: 111 - 119

   

2. Anti-HIV-1 Antibodies: An Update

   • Wanwisa Promsote
   • Megan E. DeMouth
   • Amarendra Pegu

   Leading Article 09 March 2020 Pages: 121 - 132

   

3. Targeted Biologic Therapy for Systemic Lupus Erythematosus: Emerging Pathways and Drug Pipeline

   • Kalliopi Klavdianou
   • Argyro Lazarini
   • Antonis Fanouriakis

   Leading Article 30 January 2020 Pages: 133 - 147

   

4. Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria

   • Bruno Fattizzo
   • Austin G. Kulasekararaj

   Leading Article 08 January 2020 Pages: 149 - 158

   

5. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!

   • Binita Dutta
   • Isabelle Huys
   • Steven Simoens

   Review Article Open access 02 December 2019 Pages: 159 - 170

   

6. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera^®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)

   • Jeff P. Sharman
   • Anna Marina Liberati
   • Igor Aurer

   Original Research Article Open access 09 December 2019 Pages: 171 - 181

   

7. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study

   • Vikram Muralidhar Haridas
   • Rahul Katta
   • Suresh Kankanwadi

   Original Research Article Open access 12 February 2020 Pages: 183 - 196

   

8. Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial

   • Stanley B. Cohen
   • Sebastiao C. Radominski
   • Rieke Alten

   Original Research Article Open access 14 January 2020 Pages: 197 - 207

   

9. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study

   • Srishti Joshi
   • Anurag S. Rathore

   Original Research Article 23 January 2020 Pages: 209 - 223

   

10. Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars

    • Hans C. Ebbers
    • Bjørn Fehrmann
    • Mourad Farouk Rezk

    Original Research Article Open access 10 January 2020 Pages: 225 - 233

    

11. Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis

    • Arnold Lee
    • Lesley J. Scott

    Adis Drug Evaluation 23 March 2020 Pages: 235 - 244

    

12. MYL1501D Insulin Glargine: A Review in Diabetes Mellitus

    • Sheridan M. Hoy

    Adis Drug Evaluation Open access 25 March 2020 Pages: 245 - 251

13. Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

    • Vibeke Strand
    • Joao Gonçalves
    • John D. Isaacs

    Correction Open access 26 February 2020 Pages: 253 - 253